Enoxaparin-induced skin necrosis: a fatal outcome.
Enoxaparin, a low-molecular-weight heparin used to treat and prevent deep venous thrombosis, has been evaluated in several clinical trials. Thrombosis induced by enoxaparin with no evidence of heparin-induced thrombocytopenia (HIT) is seldom described. We report a rare case in which an 89-year-old African-American female developed large, multiple, painful lesions induced by enoxaparin administration. Laboratory investigations for HIT, disseminated intravascular coagulation, protein C, protein S, factor V, factor VIII, antithrombin III, and homocysteine deficiency were negative. Unfortunately, despite aggressive management for 2 weeks, the patient developed severe sepsis and died.
Department of Medicine, Chicago Medical School/Rosalind Franklin University of Medicine and Science, North Chicago, and Mount Sinai Hospital, Chicago, IL 60608, USA. singh60660@yahoo.com
Sarabjeet
S
Singh
Meenakshi
M
Verma
Amol
A
Bahekar
Preeti
P
Agrawal
Jasleen
J
Duggal
Maria
M
Iliescu
Pam
P
Khosla
Shirin
S
Muzaffar
D001741:Black or African American; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D017984:Enoxaparin / Q000009:adverse effects* / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D009336:Necrosis; D012867:Skin / Q000473:pathology*; D020246:Venous Thrombosis / Q000188:drug therapy
D000925:Anticoagulants; D017984:Enoxaparin